Significant partnerships with Boehringer Ingelheim, Veloxis Pharmaceuticals and CKD for up to €1.4Bn in milestones (€121 M already received since 2016)
Our portfolio of clinical assets and research platforms
In Immuno-Oncology and Immuno-Inflammation
Our portfolio of clinical assets and research platforms